Tvardi Therapeutics, Inc. (NASDAQ:TVRD) stock jumps as Phase 1 data puts cash-value biotech under heavy churn
Tvardi Therapeutics, Inc. jumped as much as 89% on Tuesday after the STAT3 drug developer reported Phase 1 data for TTI-109, but the harder market signal was volume. About 53.9 million shares changed hands by early afternoon, equal to 5.7 times the 9.38 million shares outstanding listed in its latest quarterly filing.